Expansion opportunities Novartis France shows activity in international expansion through its US facilities growth and CAR-T network development. This indicates potential for cross-border partnerships, contract manufacturing, and technology transfer services to support global clinical and production scale.

Digital health partnerships There is a history of collaboration with digital therapeutics developers (Tilak Healthcare) to monitor chronic disease patients remotely. This suggests demand for digital health integration, data analytics, remote monitoring platforms, and compliant software solutions.

CAR-T and rare therapies Acquisitions and facility expansions connected to CAR-T and cell therapy ecosystems imply ongoing investment in advanced biologics. Opportunities exist for CDMO services, supply chain optimization, and manufacturing capacity for complex cell therapies.

European and global footprint France-based operations with ambitions in the US market point to a need for scalable GMP-compliant processes, regulatory support, and multi-region manufacturing capabilities to streamline global product launches.

Data and analytics readiness A tech stack spanning SAP BI, Qlik, AWS, MATLAB and R indicates strong data management capabilities. This opens doors for advanced analytics, real-world evidence generation, and AI-driven insights to improve clinical outcomes and operational efficiency.